Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene.
暂无分享,去创建一个
J. Kearney | J. Volanakis | C. Weaver | A. Szalai | M. McCrory | T. Marion | F. van Ginkel | R. Reiman
[1] A. Szalai. The antimicrobial activity of C-reactive protein. , 2002, Microbes and infection.
[2] M. Nagata,et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. , 2001, Clinical nephrology.
[3] N. Brot,et al. C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response , 2000, The Journal of experimental medicine.
[4] C. Mold,et al. C-Reactive Protein Binding to Murine Leukocytes Requires Fcγ Receptors1 , 2000, The Journal of Immunology.
[5] H. Colten,et al. Modulation of Renal Disease in MRL/lpr Mice Genetically Deficient in the Alternative Complement Pathway Factor B1 , 2000, The Journal of Immunology.
[6] D. Bharadwaj,et al. The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .
[7] P. Butler,et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity , 1999, Nature Medicine.
[8] L. Klein,et al. CD4 T Cell Tolerance to Human C-reactive Protein, an Inducible Serum Protein, Is Mediated by Medullary Thymic Epithelium , 1998, The Journal of experimental medicine.
[9] J. Volanakis,et al. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. , 1998, Journal of immunology.
[10] J. Ravetch,et al. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. , 1998, Science.
[11] T. D. Du Clos,et al. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. , 1996, Journal of immunology.
[12] M. Daha,et al. Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells. , 1996, Journal of the American Society of Nephrology : JASN.
[13] J. Volanakis,et al. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. , 1995, Journal of immunology.
[14] L. Marnell,et al. C-reactive protein binds to Fc gamma RI in transfected COS cells. , 1995, Journal of immunology.
[15] T. Lint,et al. Structure and function of the pentraxins. , 1995, Current opinion in immunology.
[16] H. Colten,et al. Cellular specificity of murine renal C3 expression in two models of inflammation. , 1994, Immunology.
[17] T. Vischer,et al. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. , 1993, The Journal of rheumatology.
[18] Y. Yazaki,et al. Interrelationship between autoepitope, DNA-binding domain, and CRP-binding domain on a histone H1 molecule. , 1993, Clinical immunology and immunopathology.
[19] H. Colten,et al. Complement gene expression in hepatic and extrahepatic tissues of NZB and NZB x W (F1) mouse strains. , 1990, Immunology.
[20] P. Butler,et al. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin , 1990, The Journal of experimental medicine.
[21] C. Dinarello,et al. Cytokines, Acute Phase Proteins, and Tissue Injury , 1990, Annals of the New York Academy of Sciences.
[22] T. D. Du Clos,et al. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. , 1989, Journal of immunology.
[23] M. Pepys,et al. Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus , 1989, The Journal of experimental medicine.
[24] T. D. Du Clos,et al. Analysis of the binding of C-reactive protein to histones and chromatin. , 1988, Journal of immunology.
[25] H. Colten,et al. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. , 1988, The Journal of clinical investigation.
[26] M. Pepys,et al. Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro. , 1988, The Journal of investigative dermatology.
[27] E. Wagner,et al. Inducible and tissue‐specific expression of human C‐reactive protein in transgenic mice. , 1987, The EMBO journal.
[28] A. Steinberg,et al. C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro , 1985, The Journal of experimental medicine.
[29] C. Mold,et al. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. , 1984, Journal of immunology.
[30] J. Kearney,et al. Demonstration of calcium-induced conformational change(s) in C-reactive protein by using monoclonal antibodies. , 1982, Molecular immunology.
[31] M. Pepys,et al. C-reactive protein in SLE. , 1982, Clinics in rheumatic diseases.
[32] J. Schifferli,et al. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. , 1982, Clinical and experimental immunology.
[33] J. Kearney,et al. Anti-DNA autoantibodies in (NZB X NZW)F1 mice are clonally heterogeneous, but the majority share a common idiotype. , 1982, Journal of immunology.
[34] G. Hughes,et al. C-reactive protein levels in systemic lupus erythematosus: a classification criterion? , 1980, Arthritis and rheumatism.
[35] V. Nussenzweig,et al. Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. , 1978, The Journal of clinical investigation.
[36] R. Siboo,et al. Isolation of mouse C-reactive protein from liver and serum. , 1977, Journal of immunology.
[37] M. Steward,et al. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice. , 1976, Clinical and experimental immunology.
[38] J. Volanakis,et al. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.
[39] B. J. Helyer,et al. Renal Disease associated with Positive Lupus Erythematosus Tests in a Crossbred Strain of Mice , 1963, Nature.
[40] A. Teppo,et al. Serum C-reactive protein is rarely lost into urine in patients with secondary amyloidosis and proteinuria , 2005, Clinical Rheumatology.
[41] C. Jacob,et al. Definition of microsatellite size variants forTnfa andHsp70 in autoimmune and nonautoimmune mouse strains , 2004, Immunogenetics.
[42] G. Appel,et al. Advances in the treatment of lupus nephritis. , 2001, Annual review of medicine.
[43] T. Vyse,et al. Genetic susceptibility to systemic lupus erythematosus. , 1998, Annual review of immunology.
[44] C. Mold,et al. Decreased autoantibody levels and enhanced survival of (NZB x NZW) F1 mice treated with C-reactive protein. , 1994, Clinical immunology and immunopathology.
[45] C. Mold,et al. C-reactive protein and the acute phase response. , 1982, Advances in internal medicine.